These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 38963839)

  • 1. A molecular glue degrader of the WIZ transcription factor for fetal hemoglobin induction.
    Ting PY; Borikar S; Kerrigan JR; Thomsen NM; Aghania E; Hinman AE; Reyes A; Pizzato N; Fodor BD; Wu F; Belew MS; Mao X; Wang J; Chitnis S; Niu W; Hachey A; Cobb JS; Savage NA; Burke A; Paulk J; Dovala D; Lin J; Clifton MC; Ornelas E; Ma X; Ware NF; Sanchez CC; Taraszka J; Terranova R; Knehr J; Altorfer M; Barnes SW; Beckwith REJ; Solomon JM; Dales NA; Patterson AW; Wagner J; Bouwmeester T; Dranoff G; Stevenson SC; Bradner JE
    Science; 2024 Jul; 385(6704):91-99. PubMed ID: 38963839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent and orally active purine-based fetal hemoglobin inducers for treating β-thalassemia and sickle cell disease.
    Lai ZS; Yeh TK; Chou YC; Hsu T; Lu CT; Kung FC; Hsieh MY; Lin CH; Chen CT; James Shen CK; Jiaang WT
    Eur J Med Chem; 2021 Jan; 209():112938. PubMed ID: 33109398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease.
    Green NS; Barral S
    Pediatr Blood Cancer; 2011 Feb; 56(2):177-81. PubMed ID: 20830771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of known mechanisms of hydroxyurea-induced fetal hemoglobin for treatment of sickle cell disease.
    Pule GD; Mowla S; Novitzky N; Wiysonge CS; Wonkam A
    Expert Rev Hematol; 2015 Oct; 8(5):669-79. PubMed ID: 26327494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology.
    Ito T; Yamaguchi Y; Handa H
    Cell Chem Biol; 2021 Jul; 28(7):987-999. PubMed ID: 34033753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fetal haemoglobin induction in sickle cell disease.
    Paikari A; Sheehan VA
    Br J Haematol; 2018 Jan; 180(2):189-200. PubMed ID: 29143315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PGC-1α agonism induces fetal hemoglobin and exerts antisickling effects in sickle cell disease.
    Sun Y; Benmhammed H; Al Abdullatif S; Habara A; Fu E; Brady J; Williams C; Ilinski A; Sharma A; Mahdaviani K; Alekseyev YO; Campbell JD; Steinberg MH; Cui S
    Sci Adv; 2024 Aug; 10(31):eadn8750. PubMed ID: 39083598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging science of hydroxyurea therapy for pediatric sickle cell disease.
    Green NS; Barral S
    Pediatr Res; 2014 Jan; 75(1-2):196-204. PubMed ID: 24252885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developing a pill to treat sickle cell disease.
    Higgs D; Kassouf M
    Science; 2024 Jul; 385(6704):27-28. PubMed ID: 38963861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators.
    Nishiguchi G; Keramatnia F; Min J; Chang Y; Jonchere B; Das S; Actis M; Price J; Chepyala D; Young B; McGowan K; Slavish PJ; Mayasundari A; Jarusiewicz JA; Yang L; Li Y; Fu X; Garrett SH; Papizan JB; Kodali K; Peng J; Pruett Miller SM; Roussel MF; Mullighan C; Fischer M; Rankovic Z
    J Med Chem; 2021 Jun; 64(11):7296-7311. PubMed ID: 34042448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisickling property of fetal hemoglobin enhances nitric oxide bioavailability and ameliorates organ oxidative stress in transgenic-knockout sickle mice.
    Dasgupta T; Fabry ME; Kaul DK
    Am J Physiol Regul Integr Comp Physiol; 2010 Feb; 298(2):R394-402. PubMed ID: 20007516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel approaches to the treatment of sickle cell disease: the potential of histone deacetylase inhibitors.
    Okam MM; Ebert BL
    Expert Rev Hematol; 2012 Jun; 5(3):303-11. PubMed ID: 22780210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The proinflammatory cytokine GM-CSF downregulates fetal hemoglobin expression by attenuating the cAMP-dependent pathway in sickle cell disease.
    Ikuta T; Adekile AD; Gutsaeva DR; Parkerson JB; Yerigenahally SD; Clair B; Kutlar A; Odo N; Head CA
    Blood Cells Mol Dis; 2011 Dec; 47(4):235-42. PubMed ID: 21945571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
    Borba R; Lima CS; Grotto HZ
    J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Candidate sequence variants and fetal hemoglobin in children with sickle cell disease treated with hydroxyurea.
    Green NS; Ender KL; Pashankar F; Driscoll C; Giardina PJ; Mullen CA; Clark LN; Manwani D; Crotty J; Kisselev S; Neville KA; Hoppe C; Barral S
    PLoS One; 2013; 8(2):e55709. PubMed ID: 23409025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease.
    Saunthararajah Y; DeSimone J
    Semin Hematol; 2004 Oct; 41(4 Suppl 6):11-6. PubMed ID: 15534852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fetal hemoglobin in sickle cell anemia: genetic studies of the Arab-Indian haplotype.
    Ngo D; Bae H; Steinberg MH; Sebastiani P; Solovieff N; Baldwin CT; Melista E; Safaya S; Farrer LA; Al-Suliman AM; Albuali WH; Al Bagshi MH; Naserullah Z; Akinsheye I; Gallagher P; Luo HY; Chui DH; Farrell JJ; Al-Ali AK; Alsultan A
    Blood Cells Mol Dis; 2013 Jun; 51(1):22-6. PubMed ID: 23465615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Novel Fetal Hemoglobin Inducers through Small Chemical Library Screening.
    Breveglieri G; Pacifico S; Zuccato C; Cosenza LC; Sultan S; D'Aversa E; Gambari R; Preti D; Trapella C; Guerrini R; Borgatti M
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33050052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of fetal hemoglobin response to hydroxyurea.
    Steinberg MH
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):8-14. PubMed ID: 9317196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of fetal hemoglobin in the treatment of sickle cell disease.
    Fathallah H; Atweh GF
    Hematology Am Soc Hematol Educ Program; 2006; ():58-62. PubMed ID: 17124041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.